ARBUTUS BIOPHARMA CORP
ABUSNASDAQTrading Snapshot
- Day Range
- $4.23 – $4.38
- 52-Week Range
- $3.50 – $5.45
- Volume (shares)
- 1,209,150
- Avg Volume (shares)
- —
- Shares Outstanding
- 198.1M
- Next Earnings
- 2026-11-11
Fundamentals Snapshot
- Annual Revenue
- $14M
- Last Q Revenue
- $1M
- P/E Ratio
- 5.6
- P/S Ratio
- 4.7x
- EPS (TTM)
- $0.78
- Dividend Yield
- —
- Dilution (1yr)
- +0.9%
ARBUTUS BIOPHARMA CORP
ABUS
StockOtter · stockotter.spaceAbout ARBUTUS BIOPHARMA CORP
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor
WARMINSTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that
Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV Cure
Arbutus Biopharma is rated Buy, leveraging a $179.1M Moderna settlement and a 46M share buyback to enhance per-share value. Imdusiran, ABUS's RNAi asset for chronic hepatitis B, targets a functional cure and could genera
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Up 5.3% – Here’s What Happened
Arbutus Biopharma Corporation (NASDAQ: ABUS - Get Free Report) shot up 5.3% during mid-day trading on Wednesday. The company traded as high as $4.93 and last traded at $4.9370. Approximately 1,416,271 shares were traded
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
WARMINSTER, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
WARMINSTER, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the
Connor Clark & Lunn Investment Management Ltd. Buys Shares of 130,023 Arbutus Biopharma Corporation $ABUS
Connor Clark and Lunn Investment Management Ltd. purchased a new position in shares of Arbutus Biopharma Corporation (NASDAQ: ABUS) in the second quarter, according to its most recent disclosure with the SEC. The firm pu